What Is Tesamorelin?

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). In the U.S., it is FDA-approved under the brand EGRIFTA SV / EGRIFTA WR for a very specific indication: reduction of excess abdominal fat in HIV-infected adults with lipodystrophy.

What Tesamorelin Is (and isn’t)

It is:

  • a prescription therapy with an FDA-labeled use for visceral adipose tissue (VAT) reduction in HIV-associated lipodystrophy

It is not:

  • an FDA-approved weight-loss medication for the general population (label includes limitations of use)

What Does the Research Show?

The FDA label summarizes evidence from multicenter, randomized, double-blind, placebo-controlled studies in the indicated population, describing reductions in abdominal fat (VAT) and outlining safety monitoring considerations.

More recent literature has also revisited tesamorelin outcomes in modern HIV treatment eras (e.g., with integrase inhibitors), reflecting ongoing clinical interest and real-world applicability.

Safety & Monitoring (High-Level)

The prescribing information details safety considerations including effects on glucose metabolism and other monitoring parameters. Any tesamorelin discussion should be grounded in the label and clinician guidance.

Who Is Tesamorelin For?

Based on the label, tesamorelin is intended for:

  • adults with HIV and lipodystrophy with excess abdominal fat (VAT)

Quick FAQ

Is tesamorelin FDA approved?
Yes — for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy (EGRIFTA SV/WR).

Is it approved for general weight loss?
No — the label includes limitations; it’s not indicated for weight loss management.

References

  • FDA prescribing information (EGRIFTA SV/WR).
  • Label limitations of use (not indicated for weight loss management).
  • Recent review/analysis in people with HIV on modern ART.

Internal link ideas: “Visceral fat vs subcutaneous fat”, “Lab monitoring basics”, “How FDA indications work”.

Related Posts